Renal Cell Carcinoma

General Cancer

Toni K. Choueiri, MD, discusses the current role of immunotherapy in the treatment of patients with renal cell carcinoma.

Treatment with the immune checkpoint inhibitor nivolumab demonstrated dose-limiting toxicities when combined with the tyrosine kinase inhibitors sunitinib or pazopanib to treat advanced or metastatic renal cell carcinoma, according to the results of a phase I parallel cohort dose escalation trial. However, both combinations showed encouraging preliminary antitumor activity.

Paul R. Eber, MD,&nbsp; discusses how the findings from the phase III CARMENA trial impact mRCC treatment and what challenges remain.<br /> &nbsp;

Patients with advanced renal cell carcinoma who received cabozantinib demonstrated improved clinical outcomes compared with patients who received everolimus in a subgroup analysis of clinical outcomes from the phase III METEOR trial.&nbsp;

Patients with metastatic renal and urothelial bladder cancer who receive antibiotics concomitantly with immune checkpoint inhibitors have shorter progression-free survival and&nbsp;overall survival rates than patients who do not, according to a poster presented at the European Congress on Immunotherapies in Cancer&trade; conference, hosted by Physicians&rsquo; Education Resource&reg;, LLC, September 21 and 22, 2018, in Barcelona, Spain.

Toni K. Choueiri, MD, discusses pivotal phase III findings for the combination of axitinib plus&nbsp;avelumab in previously untreated patients with metastatic renal cell carcinoma.

Robert A. Figlin, MD director, division of hematology/oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the considerations behind selecting an immune-oncology agent for the treatment of patients with renal cell carcinoma.

Nivolumab in combination with low-dose ipilimumab has been recommended by the European Medicines Agency&rsquo;s Committee for Medicinal Products for Human Use as treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma in the frontline setting, according to Bristol-Meyers Squibb, the developer of both immunotherapy agents.

Distinct subgroups of patients with renal cell carcinoma defined by gene expression signatures were correlated with improved progression-free survival with immunotherapy or a targeted agent, an analysis of the phase II&nbsp;IMmotion151 trial showed.<br /> &nbsp;

According to topline findings from the phase III TIVO-3 trial,&nbsp;tivozanib (Fotivda) reduced the risk of disease progression or death by 26% compared with sorafenib (Nexavar) in patients with highly refractory advanced or metastatic renal cell carcinoma.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the potential for immunotherapy/TKI combinations in the treatment of advanced renal cell carcinoma.

James L. Wade III, MD, FACP, FASCO, discusses the importance of clinical trials in the community.

Ulka Vaishampayan, MD,&nbsp;discussed the data reported from the phase Ib JAVELIN Solid Tumor trial at the ESMO 2018 Congress and addressed how these data will affect the treatment landscape for patients with advanced RCC.

In an interview with&nbsp;<em>Targeted Oncology,&nbsp;</em>Brian I. Rini, MD, discussed these core findings from the IMmotion 151 trial he presented at the conference, as well as the implications of these findings in RCC moving forward.

Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses how data should be looked at between 2 combinations for the treatment of renal cell carcinoma. He says atezolizumab plus bevacizumab will never be compared head to head with ipilimumab plus nivolumab.